中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas

文献类型:期刊论文

作者Wang, Yuxiang1; Zhang, Xu1; Ma, Qingyang2; Zhang, Xi1; Yang, Chunhao1; Tan, Cun1; Hu, Landing2; Ding, Jian1; Meng, Linghua1
刊名MOLECULAR CANCER THERAPEUTICS
出版日期2019-12-01
卷号18期号:12页码:2
ISSN号1535-7163
DOI10.1158/1535-7163.TARG-19-A116
WOS研究方向Oncology
语种英语
WOS记录号WOS:000510047200104
出版者AMER ASSOC CANCER RESEARCH
源URL[http://119.78.100.183/handle/2S10ELR8/281287]  
专题中国科学院上海药物研究所
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Wang, Yuxiang,Zhang, Xu,Ma, Qingyang,et al. HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas[J]. MOLECULAR CANCER THERAPEUTICS,2019,18(12):2.
APA Wang, Yuxiang.,Zhang, Xu.,Ma, Qingyang.,Zhang, Xi.,Yang, Chunhao.,...&Meng, Linghua.(2019).HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas.MOLECULAR CANCER THERAPEUTICS,18(12),2.
MLA Wang, Yuxiang,et al."HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas".MOLECULAR CANCER THERAPEUTICS 18.12(2019):2.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。